Evercore ISI Boosts Natera (NASDAQ:NTRA) Price Target to $250.00

Natera (NASDAQ:NTRA) had its price objective boosted by equities researchers at Evercore ISI from $190.00 to $250.00 in a report released on Friday,Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s price objective points to a potential upside of 24.75% from the company’s current price.

Other analysts have also issued reports about the stock. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. BNP Paribas Exane upgraded Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price for the company in a report on Monday, October 27th. BTIG Research increased their price objective on Natera from $210.00 to $230.00 and gave the company a “buy” rating in a research note on Friday. Piper Sandler reaffirmed an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, BNP Paribas raised Natera to a “hold” rating and set a $172.00 price target for the company in a research report on Monday, October 27th. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $201.21.

Natera Price Performance

NTRA stock traded up $1.92 during mid-day trading on Friday, hitting $200.40. 1,601,776 shares of the stock were exchanged, compared to its average volume of 1,420,866. The business has a fifty day moving average price of $177.12 and a 200 day moving average price of $163.28. Natera has a 12 month low of $125.38 and a 12 month high of $203.23. The stock has a market capitalization of $27.50 billion, a price-to-earnings ratio of -104.90 and a beta of 1.75.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, November 6th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Natera will post -1.49 EPS for the current fiscal year.

Insider Activity

In related news, Director Rowan E. Chapman sold 2,750 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the sale, the director owned 6,015 shares of the company’s stock, valued at $1,004,444.85. This trade represents a 31.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 160,703 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the completion of the transaction, the chief executive officer directly owned 144,816 shares of the company’s stock, valued at approximately $28,957,407.36. This trade represents a 52.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 224,889 shares of company stock worth $43,232,062. Corporate insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

Several large investors have recently added to or reduced their stakes in the company. Bank of Jackson Hole Trust bought a new position in shares of Natera in the first quarter worth about $29,000. TCTC Holdings LLC lifted its position in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after buying an additional 124 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 106 shares during the last quarter. Hilltop National Bank bought a new stake in shares of Natera during the 2nd quarter worth approximately $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in Natera during the 2nd quarter valued at about $36,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.